Sophia Genetics SA

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SOPHiA GENETICS excels in Q4 2022, eyes biopharma growth

SOPHiA GENETICS reported strong financial performance in Q4 2022 and full-year 2022, driven by revenue growth, strategic partnerships, and operational efficiency improvements.
The company's focus on oncology and rare diseases, along with its multimodal approach and commitment to customer satisfaction, positions it well for sustained growth and value creation.
While facing challenges in maintaining growth momentum and managing operational metrics, SOPHiA has significant opportunities for expansion, partnerships, and leveraging AI for platform enhancement.

Sophia Genetics reports strong Q1 performance and eyes pharma growth

Sophia Genetics delivered strong Q1 results with revenue growth and customer expansions.
The company's focus on innovation and strategic partnerships positions it well for future growth.
While facing macro challenges and seasonal variability, Sophia Genetics remains optimistic about revenue growth.
Pharma partnerships and global presence offer significant growth opportunities for the company.

Sophia Genetics reports robust Q2 growth and strategic partnerships

Sophia Genetics delivered strong Q2 results with revenue growth and improved operating loss, driven by customer expansion and high growth areas like HRD testing and liquid biopsy.
While facing financial challenges, the company is actively managing costs and pursuing opportunities in innovative initiatives like DEEP-Lung-IV and MRD testing applications.
With a focus on sustaining growth and profitability, Sophia Genetics aims to leverage its strengths in genomics analytics and strategic partnerships to capitalize on market opportunities.
Investor confidence is reinforced by the company's reiterated annual guidance and expectations of continued growth, positioning Sophia Genetics for future success.

Sophia Genetics reports strong Q3 growth and strategic partnerships

Sophia Genetics delivered robust Q3 results, showing growth in revenue, customer adoption, and strategic partnerships.
Despite challenges in operating losses and lack of 2024 guidance, the company remains focused on sustainable growth and profitability.
Opportunities in precision medicine applications, FDA oversight alignment, and strong sales metrics position Sophia Genetics for continued success.

SOPHiA GENETICS reports strong Q4 earnings, eyes global expansion

SOPHiA GENETICS showcased robust financial performance, operational efficiency, and strategic growth initiatives in Q4 2023.
The company's focus on innovation, global expansion, and customer acquisition positions it well for future growth and market leadership.
Challenges in financial management and technology adaptation require careful navigation for sustained profitability and market competitiveness.
Opportunities in product expansion, market penetration, and strategic partnerships offer avenues for continued revenue growth and market expansion.

SOPHiA GENETICS reports solid Q1 performance and strategic growth plans

SOPHiA GENETICS reported solid Q1 performance with revenue growth to $15.8 million, strong bookings, and new logos signed.
Despite challenges in setup times and biopharma delays impacting revenue slightly, the company maintains full-year revenue guidance and operational targets.
Opportunities lie in emerging sequencing platforms adoption, new clinical business bookings, and potential acquisitions for growth and market leadership.
Overall, SOPHiA's strategic actions, competitive strengths, and commitment to sustainable growth position the company for continued success and expansion.

SOPHiA Genetics addresses revenue challenges, eyes growth opportunities in genomics

SOPHiA Genetics navigated challenges in Q2 with a focus on strategic actions and new opportunities. Despite revenue setbacks, the company is optimistic about future growth drivers and market initiatives. The revised full-year revenue outlook reflects a commitment to cost management and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Jennifer Pottage - Head of IR Jurgi Camblong - Co-Founder, CEO and Director Ross Muken - Senior VP and CFO Conference Call Participants Dan Brennan - Cowen Tejas Savant - Morgan Stanley Julia Chen - JPMorgan Operator Thank you for standing by, and welcome to the SOPHiA GENETICS First Quarter Fiscal 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

SOPHiA GENETICS SA (SOPH) CEO Jurgi Camblong on Q1 2022 Results - Earnings Call Transcript

BOSTON and LAUSANNE, Switzerland , May 5, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cosséry to its Board of Directors. The Board of Directors will propose the appointment of Mr.

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors

BOSTON and LAUSANNE, Switzerland , April 26, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, has reached the milestone of one million genomic profiles analyzed by its SOPHiA DDM™ Platform, securing its position as one of the largest knowledge sharing platforms connecting thousands of healthcare professionals and researchers across more than 70 countries. Founded in 2011, SOPHiA GENETICS set out to create a world where every clinician has a multidimensional understanding of diseases by integrating data and sharing insights for the benefit of patients across the globe.

SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM™ Platform

BOSTON and LAUSANNE, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal 2022 before U.S. markets open on Tuesday, May 10, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time.

SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2022 on May 10, 2022

SOPHiA GENETICS SA (SOPH) CEO Jurgi Camblong on Q4 2021 Results - Earnings Call Transcript

Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 2021 2022 Guidance Reaffirmed

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results

The intended collaboration aims to help improve patient care by enhancing next-generation sequencing research for cancer care and expanding data sources for precision medicine. BOSTON, ALISO VIEJO, Calif.

SOPHiA GENETICS and REALM IDx Sign Letter of Intent to Collaborate in Accelerating Cancer Research

BOSTON, LAUSANNE, Switzerland and TAIPEI CITY, Taiwan, March 9, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH) today announced that SOFIVA GENOMICS, which is one of the largest genetic testing companies in Taiwan aiming to provide genetic testing to clinicians, is the first institution in Asia Pacific to adopt SOPHiA GENETICS' technology to support HRD testing. SOFIVA GENOMICS has been deeply involved in the field of clinical medicine and cancer monitoring for many years and found great success while implementing the solution for advanced HRD (Homologous Recombination Deficiency) detection using deep learning with the SOPHiA DDM Platform.

SOPHiA GENETICS HRD Solution Adopted in Asia Pacific

BOSTON and LAUSANNE, Switzerland, March 04, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong will participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16 at 11:15 a.m. ET/5:15 p.m. CET at the Loews Miami Beach Hotel in Miami, FL, United States.

SOPHiA GENETICS to Participate in Fireside Chat at Barclays Global Healthcare Conference

The SOPHiA DDM HRD Solution offers cost-effective, accurate, reliable, timely, and easily implementable in-house results to empower better clinical research decisions BOSTON and LAUSANNE, Switzerland, Feb. 24, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples.

SOPHiA GENETICS Launches New Deep Learning Capabilities to Support the Detection of Homologous Recombination Deficiencies

BOSTON, LAUSANNE, Switzerland, and HIROSHIMA, Japan, Feb. 22, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders. Hiroshima University is home to one of the largest university research institutes in the field of radiation biomedical science in Japan.

First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus Solution

BOSTON and LAUSANNE, Switzerland, Feb. 16, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the fourth quarter and full year 2021 before U.S. markets open on Tuesday, March 15, 2022. SOPHiA will host a conference call and live webcast to discuss its financial results as well as business outlook beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time.

SOPHiA GENETICS to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

BOSTON and LAUSANNE, Switzerland and BORDEAUX, France and MARSEILLE, France, Feb. 1, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, have announced, in conjunction with Assises de Génétique, an extension of their partnership with Institut Paoli Calmettes (IPC), one of the 18 French Cancer Comprehensive Centers (CLCC), to further support the implementation, automatization, and accreditation of solid tumor tests, to include lung, breast, ovarian and onco-hematological cancers. Recently named a Reference Medical Biology Laboratory, the oncogenetic laboratory of Institut Paoli Calmettes manages hereditary cancers and both solid tumor and myeloid/lymphoid hematologic malignancies.

Institut Paoli Calmettes Extends Partnership with SOPHiA GENETICS

BOSTON and LAUSANNE, Switzerland, Jan. 26, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that democratizes data-driven medicine, today announced that Ken Freedman has been appointed Chief Revenue Officer. With a background in serving some of the most innovative providers of technology to the world-wide media space, Ken brings more than 25 years of sales, marketing, and executive management experience.

SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue Officer

BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT04994795). Since officially launching last month, 12 sites across 5 countries have already signed up for participation in the study.

SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study

BOSTON and LAUSANNE, Switzerland, Jan. 10, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced key additions to their leadership team with the hiring of Peter Casasanto as Chief BioPharma Officer and Abhimanyu (Abhi) Verma as Chief Technology Officer. The additions are part of SOPHiA GENETICS' strategy to enhance its business in the pharmaceutical industry.

Executive Team Hires at SOPHiA GENETICS to Enhance BioPharma Business

BOSTON and LAUSANNE, Switzerland, Dec. 29, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), announced today Chief Executive Officer and Co-Founder Dr. Jurgi Camblong and Chief Financial Officer Ross Muken, will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. The virtual presentation will begin at 8:15 a.m. ET/2:15 p.m. CET on Tuesday, January 11, 2022 and will be available live and archived on SOPHiAGENETICS.COM, in the Investor Relations section.

SOPHiA GENETICS to Present at the 40th Annual J.P. Morgan Healthcare Conference

Study to leverage deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer Large-scale, multicentric real-world study aims to enroll 4,000 patients from approximately 30 sites across North America, Europe, and Latin America BOSTON and LAUSANNE, Switzerland, Dec. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today the launch of their DEEP-Lung-IV clinical study (NCT04994795). The study leverages deep learning-enabled analysis of the aggregation of multimodal clinical, biological, genomic and radiomics data to identify and validate predictive signatures associated with response to immunotherapy and prognosis of patients with metastatic non-small cell lung cancer (NSCLC).

SOPHiA GENETICS Announces Launch of DEEP-Lung-IV Multimodal Clinical Study

Symposium to address how new AI-powered analytic and workflow solutions for clinical and biopharma markets are advancing data-driven medicine Symposium encapsulates SOPHiA GENETICS and GE Healthcare alliance to provide joint solutions and multimodal analytics to healthcare providers and biopharma companies CHICAGO, Nov. 29, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they will be hosting a joint symposium with GE Healthcare titled "Advancing data-driven medicine: unlocking the potential of multimodal digital health data sets by combining longitudinal radiomics and genomics data with AI-powered analytics," during the Radiological Society of North America 2021 Annual Meeting at 9:30am CT on Wednesday, December 1. The symposium will reflect on recent advances in multimodal clinical research and the role of the radiologist in this healthcare revolution.

SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021

SOPHiA GENETICS SA (SOPH) CEO Jurgi Camblong on Q3 2021 Results - Earnings Call Transcript

New bioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation BOSTON and LAUSANNE, Switzerland, Nov. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they have extended their SOPHiA DDM ™ Universal Whole Exome analytical capabilities to include industry leading exome SureSelect Human All Exon v8 by Agilent. The new SOPHiA GENETICS pipeline is tailored to the unique features of this product to maximize support for Agilent customers in automating their next generation sequencing (NGS) workflows with enhanced, cutting-edge interpretation tools for germline and cancer applications.

SOPHiA GENETICS Launches SOPHiA DDM™ for SureSelect Human All Exon v8

BOSTON and LAUSANNE, Switzerland, Oct. 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the third quarter of 2021 before market open on Wednesday, November 10, 2021. The company's management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time to discuss its results, business developments, and outlook.

SOPHiA GENETICS to Report Third Quarter 2021 Financial Results on November 10, 2021

BOSTON and LAUSANNE, Switzerland, Oct. 12, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today the launch of SOPHiA Clinical Exome Solution v3, a new genomic application that offers enhanced probe design and increased detection capabilities for a deeper investigation of Mendelian diseases. SOPHiA Clinical Exome Solution v3 combines a capture-based target enrichment kit with the analytical capabilities and interpretation-support functionalities of the SOPHiA DDM™ platform, offering deep coverage of the target regions and accurate analysis of multiple types of variants (SNVs, Indels, and CNVs) in one unique experiment.

SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases

BOSTON and LAUSANNE, Switzerland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ: SOPH), today reported financial results for the three months ended June 30, 2021.

SOPHiA GENETICS Reports Second Quarter 2021 Financial Results and Issues 2021 Guidance

BOSTON and LAUSANNE, Switzerland, Aug. 30, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

News for Sophia Genetics SA Stock (SOPH)